摘要
许多研究表明恶性肿瘤的生长、增殖等行为与激酶的活化存在密切的关系。因此,靶向抑制激酶活性可能是一种有效的抗肿瘤疗法。ROS1是一种受体酪氨酸激酶(RTK),目前已证实ROS1基因在多种恶性肿瘤中有基因重排的现象,包括恶性胶质瘤、非小细胞性肺癌(NSCLC)、肝胆管癌、胃腺癌、结肠直肠癌、炎性肌纤维母细胞瘤等。ROS1融合蛋白组成性激活可驱动细胞增殖,诱导细胞恶变、迁移、侵袭。已有研究证实,以ROS1为靶向位点的抑制剂克唑替尼对于ROS1重排阳性的NSCLC患者有明显的疗效。因此,进一步了解ROS1融合基因的表达及机制具有重要意义。
Many studies demonstrated that the growth and proliferation of malignant tumors are closely associated with the activation of kinases. h erefore, targeted inhibition of the activation of kinases could be an ef ective anti-cancer method. ROS1 is a receptor tyrosine kinase（RTK）, and it has recently been found to harbor rearrangements in a variety of human cancers such as glioblastoma, non-small cell lung cancer（NSCLC）, cholangiocarcinoma, gastricadenocarcinoma, colorectal cancer, inflammatory myofibroblastic tumor, and angiosarcoma. The constitutive activation of ROS1 fusion proteins can drive cell proliferation, and induce cell malignant transformation, migration and invasion. Recent study found that crizotinib, an inhibitor targeting ROS1 fusion proteins, had signii cant therapeutic ef ect on NSCLC patients with positive ROS1 rearrangement. h us, further understanding the expression and mechanism of ROS1 fusion gene have important signii cance.
出处
《中国普通外科杂志》
CAS
CSCD
北大核心
2016年第2期281-285,共5页
China Journal of General Surgery
基金
湖南省科学技术厅基金资助项目(2014SK3071)
关键词
受体蛋白质酪氨酸激酶类
分子靶向治疗
综述文献
Receptor Protein-Tyrosine Kinases
Gene Fusion
Molecular Targeted h erapy
Review
